Suppr超能文献

30例骨髓转移患者的临床结局

Clinical outcome of 30 patients with bone marrow metastases.

作者信息

Zhou Min Hang, Wang Zhi Hong, Zhou Hong Wei, Liu Mo, Gu Yong Jian, Sun Jun Zhong

机构信息

Department of Hematology and Oncology, The First Affiliated Hospital of The People's Liberation Army General Hospital, Beijing 100048,PR China, P.R. China.

出版信息

J Cancer Res Ther. 2018 Jun;14(Supplement):S512-S515. doi: 10.4103/0973-1482.172717.

Abstract

OBJECTIVE

Cancer patients with bone marrow metastases are rare and dismal. The study was to identify the clinical features and prognostic factors in cancer patients with bone marrow metastases.

PATIENTS AND METHODS

A total of 30 patients with bone marrow metastases were reviewed between September 2007 and September 2013. Bone marrow metastases were identified by bone marrow aspiration.

RESULTS

The median age was 56.5 years (range, 8-85 years). The two most common primary tumor sites were the stomach (7, 23.3%), breast (5, 16.7%). Bone metastases (27, 90.0%) were the most common concurrent metastases. The most common cause for bone marrow aspiration was anemia and thrombocytopenia (10, 33.3%). The median survival time was 3 months (range, 0.5-82 months). Patients with good performance status (n = 19) had a longer median survival time than patients with poor performance status (n = 11) (8 months vs. 1 months, P = 0.041). Patients with primary unknown origin (n = 5) had a significantly shorter overall survival time than patients with known origin (n = 25) (1 month vs. 6 months = 0.010). The median survival time was 9 months in the systemic therapy group (n = 21) and 1 month in the best supportive care group (n = 9) (P = 0.000).

CONCLUSION

To make primary origin clear and start systemic antitumor therapy is beneficial for patients with bone marrow metastases.

摘要

目的

骨髓转移癌患者较为罕见且预后不佳。本研究旨在明确骨髓转移癌患者的临床特征及预后因素。

患者与方法

回顾性分析2007年9月至2013年9月期间共30例骨髓转移癌患者。通过骨髓穿刺确定骨髓转移情况。

结果

患者中位年龄为56.5岁(范围8 - 85岁)。两个最常见的原发肿瘤部位是胃(7例,23.3%)、乳腺(5例,16.7%)。骨转移(27例,90.0%)是最常见的并发转移。进行骨髓穿刺最常见的原因是贫血和血小板减少(10例,33.3%)。中位生存时间为3个月(范围0.5 - 82个月)。体能状态良好的患者(n = 19)中位生存时间长于体能状态差的患者(n = 11)(8个月对1个月,P = 0.041)。原发灶不明的患者(n = 5)总生存时间显著短于原发灶明确的患者(n = 25)(1个月对6个月,P = 0.010)。全身治疗组(n = 21)中位生存时间为9个月,最佳支持治疗组(n = 9)中位生存时间为1个月(P = 0.000)。

结论

明确原发灶并开始全身抗肿瘤治疗对骨髓转移癌患者有益。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验